



Press release

APL Begins Manufacturing of Cytostatic Drugs in Region Halland

Stockholm 2011-12-01: At the end of June 2011, APL signed a contract with Region Halland and Region Västra Götaland for extemporaneous drug production for the regions' hospitals. Production of cytostatic extemporaneous drugs for the hospitals in Varberg, Halmstad, Falkenberg and Kungsbacka begins in Varberg on the 1st of December 2011. Other sterile extemporaneous drugs will be distributed from APL's facilities in Hisingsbacka.

"We are very pleased with how APL has managed the implementation project, which ensures that the cytostatic preparations will be manufactured in Varberg starting on the 1st of December 2011." says Patrik Olsson, Director of the Department of Pharmacy at Halland Hospital. "Chemotherapy is an important part of our duties at Halland Hospital. It is therefore pleasing that we have, together with APL, put in place a well-functioning manufacturing solution that will cover the whole region of Halland."

According to the agreement, APL will operate as part of the regional hospital pharmacy in order to be able to provide both sterile and non-sterile custom extemporaneous drugs. The operational launch takes place in Varberg on the 1st of December 2011, while other manufacturing units in Västra Götaland begin deploying their first batches of the drugs in March 2012.

"We are very content over having been appointed such an important task for these key municipalities. We are also pleased to begin producing the drugs in Varberg", says Eva Sjökvist Saers, Managing Director at APL. "Our collaboration with Region Halland and Region Västra Götaland has been excellent and we look forward to launching the remaining production units.

Extemporaneous pharmaceuticals, including cytostatic drugs, are important in the quest for individualized drug therapy. The final preparations of cytostatic drugs are done immediately before they are administered and the dosage is adjusted to each specific patient. Extemporaneous drugs are important for the community as a whole in that they fulfill the medical needs of patients who cannot be medicated with registered drugs. Extemporaneous drugs are prescribed in the same way as registered drugs and are manufactured with special permission from the Swedish Medical Products Agency.

For more information, please contact:

Michael Brobjer, Marketing Director & Head of Business Development
Tel: 010 - 447 96 11, E-mail: michael.brobjer@apl.se

APL is one of the leading manufacturers of extemporaneous or compounded pharmaceuticals in Europe. APL is also a leading contract manufacturer on the Swedish life science market with resources for developing, analyzing and producing drugs, as well as an established partner to pharmacies for services and products. APL has over 30 years of experience in the pharmaceutical industry, 440 employees and four production plants. All of APL's divisions contribute to medical products which improve and save lives. Please read more about us on www.apl.se.